-- 
Clal Rises Most in 4 Months as Unit Starts Trial Plan

-- B y   G w e n   A c k e r m a n
-- 
2011-07-03T14:07:30Z

-- http://www.bloomberg.com/news/2011-07-03/clal-rises-most-in-4-months-as-unit-starts-trial-plan-correct-.html
(Corrects intraday gain in second paragraph.)  Clal Biotechnology Industries Ltd. (CBI) 
rose the most in four months after saying its Trombotech unit
started recruiting patients for a Phase IIa trial of its stroke
treatment.  Clal Biotechnology advanced 3.3 percent, the most since
March 3, to 19.69 shekels at 3 p.m. Clal said Trombotechâ€™s trial
would be carried out in  Europe ,  India  and  Israel .  To contact the reporter on this story:
Gwen Ackerman in Jerusalem at 
 gackerman@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  